Review highlights darolutamide's benefits for overall survival in hormone-sensitive prostate cancer, suggesting it may improve treatment outcomes.
The article presents a review of the results of the ARASENS registration study of darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel. This is the only triplet registered in Russia for treatment of metastatic hormone-sensitive prostate cancer. Darolutamide-based triplet showed significant benefits in overall survival and progression-free survival compared to hormone and chemotherapy combination in randomized phase III trial ARASENS, as well as better progression-free survival compared to ADT and androgen signal inhibitor duplets in meta-analyses of phase III randomized trials. Patients with de novo metastatic hormone-sensitive prostate cancer and high metastatic load receive the highest clinical benefit from darolutamide in combination with ADT and docetaxel. Darolutamide-based triplet demonstrated good safety profile comparable to duplet combination of ADT and docetaxel.
No takes yet. Share an insight, caveat, or question.
Volkova et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: